News

Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association (EHA) meeting being held in Milan, Italy. The poster presentation includes data

The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help

This result represents the largest settlement of a pharmaceutical case ever for several of the involved states, and a much higher settlement for each individual state than what

In February 2013, both the firms have voluntarily recalled all lots of Omontys and suspended promotional activities in the US after postmarketing reports of serious hypersensitivity reactions including

About 93 subjects at 38 centres in 14 countries were enrolled in PETIT2, a 2-part, double-blind, randomised placebo-controlled and open-label trial, which was designed to investigate the efficacy,

The tablets, a combination of 100mg aspirin and 15mg lansoprazole, are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor. The company

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor and is currently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay. If successfully developed and approved

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat

At present there are few adequate and well-controlled studies of pharmacotherapy in preschool-age children with ADHD and the company is the process of developing design protocols for three